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1. SUMMARY 
Gastrointestinal neuroprotection involves the net effects of many mechanisms which 
protect the enteric nervous system and its cells from death, dysfunction or degeneration. 
Neuroprotection is also a therapeutic strategy, aimed at slowing or halting the progression of 
primary neuronal loss following acute or chronic diseases.  
This thesis will focus on the roles of glutamate and N-methyl-D-aspartate (NMDA) 
receptors in the intrinsic neuronal control of gastrointestinal motility; the inflammation linked 
to gastrointestinal motility changes; and the involvement of tryptophan metabolites, especially 
kynurenic acid (KynA), in the regulatory function of the enteric nervous system and the 
modulation of the inflammatory response. We have designed and conducted three 
experimental studies to investigate whether the blockade of peripheral NMDA-sensitive 
glutamate receptors alters motility changes after mechanical ileus or chemically induced 
inflammation in the large intestine, and how this modulation is accomplished. 
In Study I, we performed experiments on three groups of dogs. Group 1 served as the 
sham-operated control; in groups 2 and 3, mechanical colon obstruction was maintained for 7 
h. Group 3 was treated with the natural NMDA receptor antagonist KynA at the onset of the 
mechanical ileus. Hemodynamics and motility changes were monitored, and the activities of 
xanthine oxidoreductase (XOR) and nitric oxide synthase (NOS) were determined from tissue 
samples. The mechanical ileus induced a hyperdynamic circulatory reaction, significantly 
elevated the motility index and increased the mucosal leukocyte accumulation and the XOR 
activity. The KynA treatment augmented the tone of the colon, permanently decreased the 
motility index of the giant colonic contractions and reduced the increases in XOR and NOS 
activities. 
In Study II, the intestinal inflammatory and motility changes were examined in a rat 
model of colitis.  The macrohemodynamics, inflammatory enzyme activities (NOS and XOR) 
and colonic motility were evaluated 17 h after colitis induction with 2,4,6-
trinitrobenzenesulfonic acid (TNBS) and compared with the control conditions. The TNBS 
enema induced a systemic hyperdynamic circulatory reaction, significantly elevated the 
mucosal XOR and NOS activities and augmented the colonic motility relative to the controls. 
The NMDA receptor antagonist KynA or treatment with KynA, a blood-brain barrier-
permeable KynA analog, significantly reduced the XOR and NOS activities, decreased the 
motility and increased the tone of the colon. 
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In Study III, KynA or the synthetic analog SZR-72 was administered 6 days after 
TNBS induction. The experiments were performed on anesthetized rats that were randomized 
to control or colitis groups. Large bowel motility parameters and macrohemodynamics were 
recorded, and the nitrite/nitrate (NOx) concentration and XOR activity were determined on 
colon biopsies. TNBS induction elevated the tissue inflammatory enzyme activities and the 
level of NOx formation. The NMDA receptor antagonist treatments significantly decreased 
the signs of inflammatory activation and the levels of NOx, and normalized the rate of bowel 
movements in both NMDA receptor antagonist-treated colitis groups in the late phase of 
experimental colitis. 
Overall, the evidence suggests that gastrointestinal neuroprotection against 
inflammation and glutamate-induced neurotoxicity may be mediated synergistically through 
the blockade of NMDA receptors, and the inhibition of NOS activity and XOR-dependent 
superoxide production. These components are likewise significant factors in the 
pathomechanism of gastrointestinal inflammatory diseases and inflammation-linked motility 
alterations. Inhibition of the enteric NMDA receptors by KynA or its analogs may provide a 
novel option via which to influence intestinal hypermotility and inflammatory processes 
simultaneously. 
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2. INTRODUCTION  
Gastrointestinal (GI) motility changes can be associated with or induced by local 
inflammation. The different types of mechanical intestinal obstructions are commonly 
diagnosed during consultations or emergency surgical situations, and these syndromes could 
be accompanied by severe abdominal inflammation (Bauer et al. 2002, Madl et al. 2003). 
Moreover, irrespective of the etiology or the type of the intraperitoneal surgical intervention, 
GI motility disorders are prevailing characteristics in the postoperative period. In general, the 
essential successful treatment of these clinical entities involves normalization of the GI 
motility. However, the morbidity rates of these syndromes are still very high, and the 
therapeutic possibilities of dysmotility are still rather limited, mainly due to the incompletely 
explored pathophysiology.  
Intestinal dysmotility is also present in inflammatory bowel diseases (IBDs), Crohn’s 
disease and ulcerative colitis (Braus and Elliott, 2009). The integrity of the superficial mucosa 
is breached in these conditions, and the extending inflammatory activation (Stein et al. 1998) 
may alter the nitrergic (Boughton-Smith 1994) and the adrenergic (Jacobson et al. 1997) 
neurotransmission, thus causing modulation of the smooth muscle activity. The exact 
pathways leading to the development of inflammation-induced colon motility changes are 
unmapped, but recent studies have demonstrated that glutamatergic elements may be involved 
in the signal transduction during this condition. Glutamate, the main excitatory 
neurotransmitter in the central nervous system (CNS), is also present in the enteric nervous 
system (ENS; Giaroni et al. 2003, Liu et al. 1997) and a high proportion of the ENS neurons 
express the N-methyl-D-aspartate (NMDA)-type glutamate receptors (Giaroni et al. 2003, 
Kirchgessner et al. 2001, Sinsky et al. 1998, Wiley et al. 1991). In line with these 
observations, previous data have suggested the involvement of enhanced NMDA receptor 
activation in nociception (Li et al. 2006, Zhou et al. 2006) as a remote CNS effect of colitis 
(Coutinho et al. 1996). 
2.1. Regulation of bowel motility. The ENS 
The reflex circuitries of the ENS have been thoroughly studied in the mammalian gut 
(Furness et al. 2004, 2006, 2008). Propulsion of the bowel content involves contraction of the 
circular muscle orally to a bolus in the lumen (the ascending excitatory reflex), and relaxation 
on the anal side (the descending inhibitory reflex). Three types of stimuli (distension, 
mechanical distortion of the mucosa, and changes in luminal chemistry) can independently 
elicit polarized reflex responses in the intestine, excitation in the oral direction and relaxation 
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in the anal direction (Kunze et al. 1999). Two main patterns of activity are recognized in the 
small intestine, the fed pattern and the interdigestive state. The latter is characterized by the 
giant migrating complex (GMC), which passes along the intestine every 80-100 min in 
humans. 
The first neurons in the intrinsic nerve circuits, which are activated by appropriate 
stimuli, are the intrinsic primary afferent neurons (IPANs). They detect changes in lumenal 
chemistry, mechanical distortion of the mucosa and mechanical forces in the external 
musculature. Type II neurones are found in the myenteric and submucosal plexuses of the 
small and large intestines of all mammals (Furness 2000, Kunze et al. 1999). 
Interneurons in the myenteric plexus have been identified by structural studies. One 
type of orally directed (‘ascending’) and three types of anally directed (‘descending’) 
interneurons have been found in the small intestine. The ascending neurons are cholinergic 
and, like the descending neurons, form chains that extend along the gut (Kunze et al. 1999). 
The descending type of interneurons are involved in local motility reflexes, the conduction of 
GMCs and secretomotor reflexes, through cholinergic, nitrergic, peptidergic and 
serotoninergic neurotransmission (Costa et al. 1996, Kunze et al. 1999). 
It has subsequently been recognized that motility is automated by the pacemaker cells 
of the ENS. These are specialized cells known as interstitial cells of Cajal (ICCs), a non-
neural cell type with a similar mesenchymal origin to that of the muscle (Sanders et al. 2006, 
Thomson et al. 1998), which are distributed in specific locations within the tunica muscularis 
of the GI tract. The ICCs provide pathways for the active propagation of slow waves, are 
mediators of enteric motor neurotransmission, and play a role in afferent neural signaling. 
Ultrastructural studies have demonstrated that the neuroeffector junctions within the GI tract 
involve specialized synapses that exist between enteric nerve terminals and intramuscular 
ICCs (ICCs-IM). The ICC-IMs are coupled to smooth muscle cells via gap junctions, and 
postjunctional responses elicited in the ICC-IMs are conducted to neighboring smooth muscle 
cells (Ward et al. 2006). In the colon, the ICCs located along the submucosal surface of the 
circular muscle layer (ICC-SMs) also provide a pacemaker function (Smith et al. 1987). A 
special population of ICCs is distributed over the surface of muscle bundles and within septae 
that separate muscle bundles, and are termed ICC-SEPs (Lee et al. 2007). Functional 
neurotransmission cannot occur in the absence of these cells (Ward et al. 2000). Indeed, 
surgical manipulations of the GI tract, including intestinal resection and anastomosis, lead to 
dysmotility in association with disruption of the ICC networks (Yanagida et al. 2004). 
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Extensive physiological studies have revealed that the muscle layers of the stomach 
and intestines are dually innervated by excitatory and inhibitory motor neurons. The primary 
transmitter of excitatory motor neurons is acetylcholine (ACh), while antagonists of 
tachykinin receptors can block residual transmission. Similarly to the excitatory motor 
neurons, the inhibitory neurons have co-transmitters. The substances that can contribute to 
transmission include nitric oxide (NO), ATP, vasoactive intestinal peptide, and pituitary 
adenylyl cyclase-activating peptide. Of these, NO is most frequently implicated as primary 
transmitter (Furness et al. 1995). 
Extrinsic primary afferent neurons are found in the nodose and dorsal root ganglia and 
transmit sensory information to the CNS. The submucosal primary afferent neurons innervate 
other submucosal neurons and project to the myenteric plexus. Secretomotor neurons in the 
submucosal plexus contain choline-acetyltransferase or VIP and are innervated either directly 
or indirectly, thereby providing the neural circuitry for a secretomotor reflex (Furness et al. 
2000, Kirchgessner et al. 2001). 
 
 
Figure 1. Simplified representation of the enteric neuronal system and its connections with 
the CNS. 1. An IPAN with a cell body in the submucosal plexus; 2. an IPAN with a cell body 
in the myenteric plexus (1 and 2 are AH-type neurons); 3-5. muscle motor neurons; 6. an 
interneuron (3-6 are S-type neurons); 7. an extrinsic primary afferent neuron; S: serosa; LM: 
longitudinal muscle; MP: myenteric plexus; CM: circular muscle; SMP: submucosal plexus; 
MM: muscularis mucosae; E: intestinal epithelium, SY: sympathetic fibers; PSY: 
parasympathetic fibers. Based on the work of JB Furness (Furness 2000, Kaszaki et al. 2012). 
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2.2. Glutamate receptors in the ENS 
Glutamate is the major excitatory neurotransmitter in the mammalian CNS, and it has 
been established that higher glutamate concentrations can lead to overexcitation, which has 
implications in the development of several disorders (Coyle et al. 1993, Ozawa et al. 1998, 
Turski et al. 1993, Weinberg et al. 1999). Glutamate not only mediates neurotransmission, but 
also takes part in the regulation of cell viability (Sattler et al. 2001), differentiation (Maric et 
al. 2000) and the formation of synapses. The importance of these normal and pathological 
functions explains the need for appropriately regulated glutamate levels. The findings of Liu 
strongly supported the hypotheses that there are glutamatergic neurons in the ENS and that 
glutamate is an enteric neurotransmitter (Liu et al. 1997). It has been shown that glutamate 
receptors are distributed in the intestinal tract, and glutamate immunoreactivity has been 
detected in subsets of submucosal and myenteric neurons in the guinea-pig ileum (Moroni et 
al. 1986). Glutamatergic submucosal neurons are presumed to be intrinsic primary afferent 
neurons that project axons to the mucosa and can detect mucosal chemical and mechanical 
stimuli. 
The receptors that mediate the glutamate signal are divided into two main classes, 
which can be subdivided further according to the pharmacological agents that are able to 
activate the appropriate receptor specifically. The ionotropic receptors, such as kainate, alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA receptors are 
ligand-gated ion channels, while the metabotropic receptors are coupled to G-proteins. 
 
Figure 2. Schematic illustration of the structure of the NMDA-type glutamate receptor with 
its main distinct binding sites. The ion channel is blocked by Mg2+ in a voltage-dependent 
manner. NMDA receptor activation (binding of both glycine and glutamate) opens the 
nonselective cation channel. The activation results in the flow of Na+ and Ca2+ into the cell 
and of K+ out of the cell (Kaszaki et al. 2012). 
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2.3. Roles of NMDA receptors in the regulation of GI motility 
GI motility regulation is predominantly cholinergic in nature, but the neurons of the 
ENS have a wide variety of neurotransmitters (Furness 2006). Ionotropic NMDA-sensitive 
glutamate receptors are present and abundantly expressed on enteric cholinergic neurons (Liu 
et al. 1997, Moroni et al. 1986, Shannon et al. 1989, Wiley et al. 1991). Moreover, glutamate 
is selectively concentrated in terminal axonal vesicles and can be released after the application 
of an appropriate stimulus (Sinsky et al. 1998, Wiley et al. 1991). These early data were 
reinforced by studies demonstrating that the activation of glutamate-NMDA receptors 
enhances ACh release from myenteric neurons in the guinea-pig ileum and colon (Giaroni et 
al. 2003, Kirchgessner et al. 2001). This latter effect has been proposed as a possible 
mechanism for glutamate-induced contractions of the guinea-pig ileum (Giaroni et al. 2003, 
Liu et al. 1997, Sinsky et al. 1998, Wiley et al. 1991) and functional studies have described 
the significance of glutamate in the modulation of motor and secretory functions in the gut 
(Cosentino et al. 1995, Sinsky et al. 1998, Wiley et al. 1991). 
The GI motility response basically depends on the outcome of myenteric plexus 
activation, and the net effect combines contractile and relaxant signals. The participation of 
peripheral NMDA glutamate receptors in this mechanism is of special interest, but the exact 
mediatory pathways and concomitant neurotransmitter releases have not yet been elucidated 
clearly. In this respect, it is important to note that non-adrenergic non-cholinergic intrinsic 
innervations mediate inhibitory or relaxing responses to the peristaltic waves through nitrergic 
neurotransmission (Kohjitani et al. 2005). There is a clear link between Ca2+-dependent 
constitutive NO production and the ENS reactions (Ekblad et al. 1994, Furness et al. 2000, Qu 
et al. 1999). The NMDA receptor is associated with a cation-selective channel that gates Ca2+ 
in the resting state, and this receptor has been shown to be up to 70 times more permeable to 
Ca2+ than AMPA or kainate receptors. For transmitter release, the Ca2+-dependent neuronal 
NO synthase (nNOS) permits the rapid release of NO, a process associated with the 
translocation of cytosolic nNOS to the cell membrane. There it binds to postsynaptic density-
95 protein in intimate association with NMDA glutamate receptors, permitting a direct route 
for Ca2+ through the NMDA receptor channel to nNOS. The activation of myenteric NMDA 
receptors, followed by a massive Ca2+ influx through the NMDA receptor-ion complex, may 
stimulate NO synthesis, which in turn would increase an ACh release. An elegant study by 
Miluseva demonstrated that stimulation of the enteric NMDA receptors by glutamate resulted 
in increased NADPH-diaphorase staining (reflecting an increase in myenteric nitrergic 
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neurons) and NOS activity, in line with the enhanced ACh efflux. The NOS inhibitor Nω-
nitro-l-arginine effectively opposed both effects (Miluseva et al. 2005). Another study 
reinforced the functional linkage of peripheral NMDA receptors in the lower esophageal 
sphincter and the NO-cGMP pathway, leading to smooth muscle relaxation (Kohjitani et al. 
2005). Thus, glutamate or its endogenous receptor agonists/antagonists may participate in 
modulation of the enteric cholinergic function, since activation of the NMDA receptors 
enhances NO-dependent ACh release from the myenteric neurons in the ileum and colon 
(Giaroni et al. 2003, Kohjitani et al. 2005, Miluseva et al. 2005).  
In contrast with the above, several studies have indicated that NMDA induces 
contraction of the guinea-pig ileal smooth muscle (Moroni et al. 1986). Electrical field 
stimulation under various conditions induces contractions instead of relaxation in the lower 
esophageal sphincter, which proved sensitive to tetrodotoxin (Kohjitani et al. 2005). 
Moreover, electrically evoked ACh release was demonstrated to be inhibited by NO (Hebeiss 
et al. 1996), while in other studies NO failed to modulate the release of ACh (Mizhorkova et 
al. 2001). A feasible explanation of these contradictory observations is that smooth muscle 
relaxation is modulated in part by the extracellular production of superoxide anions, thereby 
eliminating the relaxant effect of endogenous NO. It should be added that the reaction of NO 
with superoxide radicals leads to the formation of peroxynitrite, a known inhibitor of NOS 
activity and a highly injurious molecule to a variety of cells (Beckman et al. 1990). 
Superoxide production has been reported to be triggered by NMDA and inhibited by 
superoxide dismutase (SOD) or MK801 in cultured cerebellar granule cells (Lafon-Cazal et 
al. 1993). Furthermore, nNOS catalyzes superoxide formation at lower concentrations or in 
the absence of L-arginine in a Ca2+/calmodulin-dependent manner (Pou et al. 1992). It should 
be noted that elevated xanthine oxidoreductase (XOR) activity and polymorphonuclear 
(PMN) cell accumulation are typical components of gastrointestinal inflammation, and the 
inhibition of PMN leukocyte activation and reduction of the tissue concentrations of PMN- or 
XOR-derived superoxide radicals can in turn reduce the tissue damage. In this line, the 
accumulation of glutamate with subsequent activation of the NMDA glutamate receptors can 
lead to the increased production of nitroso radicals and further formation of reactive oxygen 
species (ROS) through the stimulation of constitutive NO synthase (cNOS) and XOR 
activities (Yue et al. 2001). 
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2.4. Kynurenic acid and neuroprotection in the ENS. 
L-Tryptophan is an important essential amino acid used for protein synthesis and it is 
also a precursor of bioactive molecules. Approximately 1-2% of the intake is metabolized 
through serotonin synthesis, but most enters the kynurenine pathway, synthesizing L-
kynurenine, quinolinic acid, kynurenic acid (KynA) and NAD. The rest of the dietary 
tryptophan undergoes bacterial degradation or is excreted in the urine (Keszthelyi et al. 2009). 
Two major products of the tryptophan–L-kynurenine pathway, quinolinic acid and KynA, act 
on the glutamate receptors. The main route of this pathway generates quinolinic acid, an 
agonist of the NMDA glutamate receptors and NAD, while only a side-branch is responsible 
for KynA production.  
 
Figure 3. The L-tryptophan metabolism (Rodgers et al. 2009).   
 
KynA is an endogenous NMDA receptor antagonist (Klivényi et al. 2004) and is able 
to reduce excitotoxic damage of the CNS both in vivo (Faden et al. 1989, Simon et al. 1986) 
and in vitro (Choi et al. 1988). KynA is considered neuroprotective in neurodegenerative 
disorders (Klivényi et al. 2004), but it is practically not able to cross the blood–brain barrier 
(BBB; Fukui et al. 1991).  To date, a number of clinical data suggest that the metabolism of 
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tryptophan along the kynurenine pathway is altered in inflammatory GI disorders, too. The 
plasma level of L-kynurenine is elevated in IBD patients, and the levels are likewise increased 
in celiac disease (Forrest et al. 2002, Torres et al. 2007). However, despite these findings, the 
roles and function of KynA and other l-tryptophan metabolites in the ENS are as yet largely 
unknown. 
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3. MAIN GOALS 
The main purpose of our studies was to investigate and clarify the roles of NMDA-type 
glutamate receptors in GI motility disorders associated with inflammation. Since the 
chronology and time frame of events can be decisive factors during these conditions, we had 
to design three related series of experiments to explore the most important components of 
pathophysiological changes. 
 
1. Study I was designed to determine whether NMDA receptors play roles in 
physiological and pathophysiological GI motility changes. Our main aim was to 
follow the variations in the colonic motility as a function of time during the 
development of inflammatory reactions. With this aim, we used a large animal model 
of acute mechanical ileus to monitor inflammatory and motility changes 
simultaneously. We administered exogenous KynA to outline the in vivo consequences 
of NMDA receptor antagonism on colon motility regulation in this setup. 
2. Study II was designed to evaluate the level of acute inflammatory activation in the 
distal colon in a rodent model of experimental colitis. Our aim was to investigate 
whether alterations in NMDA receptor activation play a role in the regulation of 
intestinal motility in these settings. However, as KynA is virtually unable to cross the 
BBB, it can not provide information on possible CNS effects of NMDA receptors in 
GI regulation. To address this issue, we set out to characterize and compare the in vivo 
effects of the endogenous NMDA glutamate receptor antagonist KynA and its BBB-
permeable synthetic analog SZR-72 in the GI tract after the initial inflammatory insult. 
An additional aim was to characterize the in vivo effects of SZR-72 in the GI tract. 
The compound was originally developed to influence NMDA receptor overexcitation 
in the CNS and its peripheral ENS effects were still largely unmapped. 
3. The goal of Study III was to examine whether GI motility alterations could be 
influenced by NMDA receptor antagonism in the later period of inflammation. It is 
important to note that medical therapy typically starts after the onset of signs and 
symptoms, and experimental studies involving delayed treatment are therefore 
arguably more relevant to the clinical scenario. To address this issue, we set out to 
characterize the in vivo effects of the endogenous NMDA glutamate receptor 
antagonist KynA and its BBB-permeable synthetic analog, SZR-72, on the 
inflammatory and motility changes still present 6 days after the onset of colitis. To 
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acquire further insight into the mechanism of action of KynA, we designed in vitro 
experiments to test the direct effects of KynA on the activity of the ROS-producer 
enzyme XOR. 
4. A further aim was to provide comprehensive comparative data on the role of NMDA 
receptors in the ENS during baseline and inflammatory conditions. To this end, we 
have collected data from dogs, Wistar rats and Sprague-Dawley rats, the strains most 
commonly used for GI inflammation studies. 
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4. MATERIALS AND METHODS 
4.1. Animals 
The experiments were performed in adherence to the NIH guidelines for the use of 
experimental animals. The study was approved by the Ethical Committee for the Protection of 
Animals in Scientific Research at the University of Szeged. 
The experiments in Study I were performed on healthy, mongrel dogs of both sexes 
(average weight 12-18 kg; n=16) from the Animal House of the University of Szeged. 
The experiments of Study II were performed on male Wistar rats (average weight 300 
g; n=24). 
In Study III, male Sprague-Dawley rats (average weight 350 g; n=21) were used. The 
species, the numbers of animals in the individual groups, the interventions and the 
administered agents in the respective Studies are shown below. 
 
Studies Observation time Groups Interventions n 
Study I 7 hr 1 Sham-operated control 5 
(Dogs)  2 Mechanical ileus 6 
  3 Mechanical ileus + KynA 5 
Study II  17-23 hrs 1 Sham-operated 6 
(Wistar rats)  2 Colitis 6 
  3 Colitis + KynA 6 
  4 Colitis + SZR-72 6 
Study III  5 hrs on day 6 
(144-149 hrs) 
1 Sham-operated 5 
(Sprague-Dawley rats)  2 Colitis 5 
  3 Colitis + KynA 6 
  4 Colitis + SZR-72 5 
 
Table I. Study groups, treatments and numbers (n) of animals. 
 
4.2. Surgical preparations, experimental protocol in Study I 
Surgery was performed under sodium pentobarbital anesthesia (30 mg kg-1 iv). The left 
femoral artery and vein were cannulated for the recording of mean arterial pressure (MAP) 
18 
 
and for fluid and drug administration, respectively. A central venous catheter was introduced 
into the left jugular vein for central venous pressure (CVP) measurement. A Swan-Ganz 
thermodilution catheter was positioned into the pulmonary artery via the right femoral vein to 
measure the cardiac output (CO). 
After a midline abdominal incision, the superior mesenteric artery (SMA) was dissected 
free and an ultrasonic flow-probe was placed around the exposed SMA to measure the 
mesenteric blood flow. The level of the obstruction was marked by placing a silicone 
tourniquet catheter around the mid-transverse colon, keeping the neurovascular connections 
intact. Strain gauge transducers (Experimetria Ltd., Budapest, Hungary) were sutured with an 
atraumatic technique onto the antimesenteric side of the bowel wall to measure colonic 
motility at 10 cm proximally from the occlusion point. 
The baseline variables were determined during a 30-min control period. Group 1 (n=5) 
served as the sham-operated control. Dose-response effects (the exact concentrations of KynA 
required to yield a beneficial effect in vivo) were investigated in pilot rat studies. In groups 2 
(n=6), and 3 (n=5), complete large bowel obstruction was induced by tightening the 
tourniquet. The animals in groups 1 and 2 were treated with the vehicle for KynA, while in 
group 3, KynA (Sigma Chem. USA; 50 mg kg-1 iv in a 0.7 ml min-1 iv infusion for 30 min in 
20 ml 0.1 M NaOH with the pH adjusted to 7.2-7.4) was administered 3 h after the onset of 
ileus. The animals were observed for 7 h, the beginning of mechanical ileus denoting 0 h. 
Changes in colonic motility and hemodynamic parameters were registered hourly. At the end 
of the experiment, tissue samples were taken from the proximal part of the large bowel for the 
determination of inflammatory enzyme activities (NOS and XOR). 
4.3. Surgical preparations and experimental protocols in Studies II and III 
The animals were randomly assigned to one or other of the groups, and were deprived 
of food, but not water, for 12 h prior to the enema. Colitis was induced under transient ether 
anesthesia by the colonic instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS; 40 mg kg-1  
in 0.25 ml of 25% ethanol) through an 8-cm-long soft plastic catheter (Morris et al. 1989). 
The sham-operated groups were treated with the solvent of TNBS (0.25 ml of 25% ethanol). 
After the enemas, the rats were returned to their cages and were fed ad libitum with standard 
laboratory chow. 
The sham-operated or TNBS-treated animals in Study II were anesthetized with 
sodium pentobarbital (50 mg kg-1 bw intraperitoneally) 16 h after the enema. In Study III, 
anesthesia was started 143 h (6 days – 1 h) after the TNBS enema. For instrumentation, the 
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animals were placed in a supine position on heating pads. Tracheostomy was performed to 
facilitate spontaneous breathing, and the right jugular vein was cannulated with PE50 tubing 
for drug administration and Ringer’s lactate infusion (10 ml kg-1 h-1). A thermistor-tip catheter 
(PTH-01; Experimetria Ltd., Budapest, Hungary) was positioned into the ascending aorta 
through the right common carotid artery for CO measurements, using a thermodilution 
technique with a computer program (SPEL Advanced Cardiosys 1.4, Experimetria Ltd, 
Budapest, Hungary). The left common carotid artery was isolated and an ultrasonic flow 
probe (1RS; Transonic Systems Inc., Ithaca, NY, USA) filled with acoustic coupling gel was 
placed on the carotid artery. The right femoral artery was cannulated with PE40 tubing for 
MAP and heart rate measurements. After a midline abdominal incision, a strain-gauge 
transducer (Experimetria Ltd, Budapest, Hungary) was sutured onto the colonic wall by an 
atraumatic technique with seromuscular stitches 3 cm distal from the cecum for colonic 
motility detection. After a 30-min recovery period following the end of instrumentation, 
hemodynamic and colonic motility changes were monitored for 6 h (data were recorded for 15 
min hourly) in Study II and for 5 h in Study III.  
The groups in the two rodent studies were basically the same; the only difference 
between the protocols was the time frame of the experiments (17-23 h or 5 h at the beginning 
of day 6 after the enema (144-149 h), respectively). In both rat studies, group 1 served as a 
sham-operated control and group 2 was an untreated colitis group. In group 3, the animals 
received 25 mg kg-1 of KynA (Sigma-Aldrich Inc, St. Louis, MO, USA) dissolved in 0.1 M 
NaOH in a total volume of 1 ml, with the pH adjusted to 7.2-7.4. Group 4 was treated iv with 
10 mg kg-1 of SZR-72 in a 1 ml h-1 infusion for 60 min. SZR-72 (2-(2-N,N-
dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride; synthetized by the 
Institute of Pharmaceutical Chemistry, University of Szeged (Patent No. 104448-
1998/Ky/me), was dissolved in 1 ml of saline and the pH was adjusted to 7.2-7.4. The 
infusion of KynA or SZR-72 started 60 min after the baseline measurements (at 18 h or 1 h on 
day 6 (145 h) after the enema, respectively) and lasted for 60 min.  
4.4. Measurements 
4.4.1. Hemodynamic measurements 
In Study I, the MAP, CVP, portal venous pressure and SMA blood flow were monitored 
continuously and registered with a computerized data-acquisition system (Haemosys 1.17; 
Experimetria Ltd., Budapest, Hungary). The CO was determined by thermodilution, using a 
SPEL Advanced Cardiosys 1.4 computer (Experimetria Ltd., Budapest, Hungary). The total 
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peripheral vascular resistance (TPR) was calculated via the standard formula (MAP-
CVP/CO). 
In Studies II and III, the pressure signals (BPR-02 transducer; Experimetria Ltd, Budapest, 
Hungary) and carotid artery flow signals (T206 Animal Research Flowmeter; Transonic 
Systems Inc., Ithaca, NY, USA) were measured continuously and registered with a 
computerized data-acquisition system (Experimetria Ltd, Budapest, Hungary). Total 
peripheral vascular resistance was calculated by using the standard formula. 
4.4.2. Colonic motility measurements 
 The strain-gauge transducer sutured onto the colon was connected to an SG-M bridge 
amplifier, and the signals were recorded continuously with a computerized data-acquisition 
system (SPEL Advanced Haemosys 1.72; Experimetria Ltd, Budapest, Hungary). At each 
time point, the duration of sampling was 10 min, with a sampling frequency of 500 Hz; the 
signal analysis was performed off-line. The qualitative characterization of the motility pattern 
was based on several components, including the amplitude, the frequency and the tone. The 
amplitude and frequency contractions were calculated as a function of time, while the tone of 
the colon was given by the mean value of the minima of the motility curves (Palásthy et al. 
2006, Kaszaki et al. 2008). 
4.4.3. Preparation of colon biopsies 
Colon biopsies kept on ice were homogenized in phosphate buffer (pH 7.4) containing 
Tris-HCl (50 mM, Reanal, Budapest, Hungary), EDTA (0.1 mM),  dithiotreitol (0.5 mM), 
phenylmethylsulfonyl fluoride (1 mM), soybean trypsin inhibitor (10 μg ml-1) and leupeptin 
(10 μg ml-1, Sigma-Aldrich GmbH, Steinheim, Germany). The homogenate was centrifuged at 
4 °C for 20 min at 24,000 g (Amicon Centricon-100, Millipore Corporation, Bedford, MA, 
USA). Tissue nitrite/nitrate (NOx) was determined in the supernatant. 
4.4.4. Tissue XOR activity 
The XOR activity was determined in the ultrafiltered, concentrated supernatant by a 
fluorometric kinetic assay based on the conversion of pterine to isoxanthopterine in the 
presence (total XOR) and absence (xanthine oxidase (XO) activity) of the electron acceptor 
methylene blue (Beckman et al. 1989). 
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4.4.5. In vitro XOR activity examination. Inhibition of XOR activity  
The activity of 10 mU XOR was measured in the presence of 5 μM xanthine. The 
chemiluminescence was detected in the presence or in the absence of KynA or allopurinol in 
the 1 μM - 1 mM concentration range in 50 mM K-phosphate buffer containing 0.1 mM 
EDTA, pH=7.4 (experimental buffer solution). A previously mixed aliquot of the components 
(10 mU XOR/5 μM xanthine) was injected into a plastic minivial with a diameter of 10 mm 
containing luminol (100 μM) dissolved in the experimental buffer solution (pH=7.4) and was 
inserted into a common Packard potassium glass vial. The total volume of the reaction 
mixture was 1 ml (Ferdinandy et al. 2000, Onody et al. 2003). 
Chemiluminescence was followed for 5 minutes in the tritium channel, in a Packard 
Tri-Carb 2100 Model liquid scintillation counter set in the out-of-coincidence mode. All 
manipulations were performed in a dark room with minimal light. Measurements were started 
after dark adaptation of the sample for 2 min. The luminol blank was determined before 
adding the sample and the measured count was subtracted from the total output. 
Chemiluminescence was detected in the presence or in the absence of KynA or allopurinol in 
the 1 μM - 1 mM concentration range. Results were expressed as inhibition (as a percentage 
of the control). 
4.4.6. Measurement of tissue NO products 
The stable end-products of NO, NOx, were determined in the colonic homogenate by 
the Griess reaction in Study III. This assay depends on the enzymatic reduction of nitrate to 
nitrite, which is then converted into a colored azo compound detected spectrophotometrically 
at 540 nm. Total NOx was calculated and expressed in µmol (mg protein)-1 (Moshage et al. 
1995). 
4.4.7. NOS activity measurements 
NO formation in the intestinal tissues was measured via the conversion of [3H]L-
citrulline from [3H]L-arginine according to the method of Szabo et al. (1993). Briefly, large 
bowel biopsies kept on ice were homogenized in phosphate buffer (pH 7.4) containing 50 mM 
Tris-HCl (Reanal, Budapest, Hungary), 0.1 mM EDTA (Serva Feinbiochemica GmbH, 
Heidelberg, Germany), 0.5 mM dithiotreitol, 1 mM phenylmethylsulfonyl fluoride, 10 μg ml-1 
soybean trypsin inhibitor and 10 μg ml-1 leupeptin. The homogenate was centrifuged at 4 oC 
for 20 min at 24,000g and the supernatant was loaded into centrifugal concentrator tubes 
(Amicon Centricon-100; 100,000 MW cut-off ultrafilter; Millipore Corporation, Bedford, 
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MA, USA). The tubes were centrifuged at 900g for 150 min and the concentrated supernatant 
was washed out from the ultrafilter with 250 μl homogenizing buffer. The samples were 
incubated with a cation-exchange resin (Dowex AG 50W-X8, Na+ form; The Dow Chemical 
Company, Midland, MI, USA) for 5 min to deplete endogenous L-arginine. The resin was 
separated by centrifugation (1500g for 10 min) and the supernatant containing the enzyme 
was assayed for NOS activity. 
For the Ca2+-dependent eNOS activity, 50 μl enzyme extract and 100 μl reaction 
mixture (pH 7.4, containing 50 mM Tris-HCl buffer, 1 mM NADPH, 10 μM 
tetrahydrobiopterin, 1.5 mM CaCl2, 100 U ml-1 calmodulin and 0.5 μCi [3H]L-arginine 
(Amersham U.K., specific activity 63 Ci mmol-1)) were incubated together for 60 min at 37 
oC. The reaction was stopped by the addition of 1 ml ice-cold HEPES buffer (pH 5.5) 
containing 2 mM EGTA and 2 mM EDTA. Measurements were performed with the 
nonselective NOS inhibitor NNA (Sigma-Aldrich GmbH, Steinheim, Germany, 3.2 mM) to 
determine the extent of [3H]L-citrulline formation independent of the NOS activity. Inducible 
NOS (iNOS) was measured without Ca2+-calmodulin and with EGTA (8 mM). 1 ml reaction 
mixture was applied to Dowex cation-exchange resin (AG 50W-X8, Na+ form; The Dow 
Chemical Company, Midland, MI, USA) and eluted with 2 ml distilled water. The eluted 
[3H]L-citrulline activity was measured with a scintillation counter (Tri-Carb Liquid 
Scintillation Analyzer 2100TR/2300TR, Packard Instrument Co, Meriden, CT, U.S.A.). 
Protein contents of samples were determined by the Lowry method. 
4.5. Statistical analysis 
Data analysis was performed with a statistical software package (SigmaStat for 
Windows; Jandel Scientific, Erkrath, Germany). The distribution of our experimental data 
was analyzed by the Kolmogorov-Smirnov normality test. Failure of the normality test 
indicated non-parametric distribution of the data. Accordingly, we employed nonparametric 
statistical tests. Friedman repeated measures analysis of variance on ranks was applied within 
groups. Time-dependent differences from the baseline for each group were assessed by 
Dunn’s method, and differences between groups were analyzed with Kruskal-Wallis one-way 
analysis of variance on ranks, followed by Dunn’s method for pairwise multiple comparison. 
In the Figures, median values and 75th and 25th percentiles are given; p values <0.05 were 
considered significant. 
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5. RESULTS 
5.1. Hemodynamics 
In Study I, the administration of KynA did not significantly influence the MAP in 
animals with mechanical ileus and, similarly, treatment with KynA did not influence the 
colitis-induced changes in MAP as compared with the colitis group in Studies II and III (Table 
II). 
In Study I, the obstruction of the large bowel led to a significant CO elevation after 5 
h, and KynA treatment did not influence this process (Table IV). However, the treatment with 
the nonselective NMDA receptor antagonist inhibited the obstruction-induced decrease in 
TPR. The changes were statistically significant 6 h after obstruction (Table III). 
On day 1 of colitis, the CO was significantly higher than in the sham-operated group 
(Table IV), while the TPR was significantly lower in the TNBS-treated groups in comparison 
with the sham-operated group. In this case, treatment with KynA did not influence the colitis-
induced changes in CO and TPR as compared with the colitis group. At the same time, a 
significant increase in TPR relative to the colitis group evolved 19 h after colitis induction 
after SZR-72 treatment (Table III). 
There were no significant between-group differences in CO (Table IV) or TPR (Table 
III) 6 days after the vehicle enema instillation or colitis induction, before the start of NMDA 
receptor antagonist treatment. 
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Table II. Changes in MAP [mmHg]. x p<0.05 between groups vs sham-operated 
group; # p<0.05 between NMDA antagonist-treated groups 
 Parameters Baseline 1 h after 
treatment 
start 
2 h after 
treatment 
start  
At the end 
of the 
experiment 
MAP in Study I 
Sham-operated Median 
25p; 75p 
138 
131; 147 
135 
123; 148 
135 
123; 135 
130 
116; 128 
Mechanical ileus  Median 
25p; 75p 
146 
145; 151 
138 
137; 143 
134 
129; 139 
134 
129; 142 
Mechanical ileus + 
KynA 
Median 
25p; 75p 
144 
128; 159 
136 
115; 153 
125 
104; 141 
129 
103; 155 
MAP in Study II 
Sham-operated Median 
25p; 75p 
134 
131; 137 
129 
128; 134 
129 
128; 131 
126 
125; 129 
Colitis Median 
25p; 75p 
112 x 
98; 117 
113 x 
98; 123 
108 x 
91; 119 
106 x 
98;119 
Colitis + KynA Median 
25p; 75p 
119 x 
110; 122 
118 
106; 123 
113 x 
105; 125 
110 x 
106; 116 
Colitis + SZR-72 Median 
25p; 75p 
116 
103; 125 
113 
107; 124 
115 x 
109; 122 
111 x 
105; 114 
MAP in Study III  
Sham-operated Median 
25p; 75p 
121 
117; 128 
123 
108; 130 
118 
113; 129 
122 
119; 134 
Colitis Median 
25p; 75p 
123 
107; 123 
120 
107; 123 
118  
106; 126 
116 
110;121 
Colitis + KynA Median 
25p; 75p 
129 
123; 130 
127 
120; 130 
121 
115; 127 
119 
117; 124 
Colitis + SZR-72 Median 
25p; 75p 
123 
122; 126 
118 
116; 126 
124 
121; 129 
120 
115; 123 
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Table III. Changes in TPR [mmHg (ml min)-1]. x p<0.05 between groups vs sham-operated 
group; # p<0.05 between NMDA antagonist-treated groups and colitis group. 
 Parameters Baseline 1 h after 
treatment 
start 
2 h after 
treatment 
start  
At the end 
of the 
experiment 
TPR in Study I 
Sham-operated Median 
25p; 75p 
0.91 
0.90; 1.06 
1.07 
1.05; 1.18 
1.14 
0.82; 1.18 
1.03 
0.94; 1.14 
Mechanical ileus  Median 
25p; 75p 
0.93  
0.86; 1.01 
0.91 
0.89; 1.06 
0.80 x 
0.70; 0.87 
0.69 x 
0.66; 0.78 
Mechanical ileus + 
KynA 
Median 
25p; 75p 
0.93 
0.89; 0.97 
1.05 
0.99; 1.07 
1.03 
0.99; 1.08 
0.98 
0.93; 1.09 
TPR in Study II 
Sham-operated Median 
25p; 75p 
2.20 
1.73; 2.78 
2.11 
1.58; 2.59 
2.34 
1.84; 2.66 
2.43 
2.07; 2.58 
Colitis Median 
25p; 75p 
1.47 x 
1.36; 1.57 
1.45 x 
1.42; 1.55 
1.47 x 
1.28; 1.57 
1.45 x 
1.13; 1.60 
Colitis + KynA Median 
25p; 75p 
1.59 x 
1.36; 1.71 
1.54 x 
1.32; 1.69 
1.55 x 
1.22; 1.75 
1.50 x 
1.18; 1.57 
Colitis + SZR-72 Median 
25p; 75p 
1.55 x 
1.47; 1.73 
1.66 #  
1.61; 1.78 
1.77 
1.63; 2.00 
1.86 
1.45; 2.03 
TPR in Study III  
Sham-operated Median 
25p; 75p 
1.89  
1.56; 2.30 
1.67 
1.46; 1.80 
1.64 
1.40; 2.27 
2.05 
1.77; 2.22 
Colitis Median 
25p; 75p 
1.82 
1.43; 2.25 
1.89 
1.21; 2.09 
1.86 
1.33; 2.39 
1.67 
1.08; 2.76 
Colitis + KynA Median 
25p; 75p 
1.69 
1.29; 2.87 
2.15 
1.34; 2.17 
1.90 
1.67; 2.62 
2.25 
1.50; 2.27 
Colitis + SZR-72 Median 
25p; 75p 
1.85 
1.61; 3.05 
1.93 
1.30; 2.79 
1.61 
1.09; 2.84 
1.76 
1.16; 2.13 
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Table IV. Changes in CO [ml kg-1]. x p<0.05 between treated and sham-operated group. 
 Parameters Baseline 1 h after 
treatment 
2 h after 
treatment  
End of the 
experiment 
CO in Study I 
Sham-operated Median 
25p; 75p 
133 
119; 148 
122 
118; 136 
127 
119; 133 
125 
117; 126 
Mechanical ileus  Median 
25p; 75p 
141  
131; 150 
154 
139; 173 
153 x 
142; 160 
168 x 
137; 181 
Mechanical ileus + 
KynA 
Median 
25p; 75p 
136 
125; 147 
144 
136; 149 
145 
138; 152 
144 x 
142; 160 
CO in Study II 
Sham-operated Median 
25p; 75p 
154 
120; 188 
147 
125; 185 
151 
106; 190 
165 
133; 188 
Colitis Median 
25p; 75p 
215 x 
197; 244 
224 x 
211; 275 
228 x 
206; 260 
235 x 
208; 255 
Colitis + KynA Median 
25p; 75p 
205 
184; 220 
196 
185; 241 
217 
193; 242 
239 x 
226; 245 
Colitis + SZR-72 Median 
25p; 75p 
215 
183; 227 
185 
173; 203 
195 
188; 202 
193 
181; 223 
CO in Study III  
Sham-operated Median 
25p; 75p 
190  
164; 213 
194 
167; 223 
178 
162; 208 
167 
158; 183 
Colitis Median 
25p; 75p 
222 
213; 230 
227 
198; 246 
214 
197; 223 
201 
141; 262 
Colitis + KynA Median 
25p; 75p 
205 
187; 232 
212 
183; 237 
223 
210; 233 
157 
149; 177 
Colitis + SZR-72 Median 
25p; 75p 
211 
143; 269 
219 
161; 288 
192 
152; 238 
221 
191; 256 
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5.2. Colonic motility changes 
The colon motility index and the amplitude of the GMCs did not change in the sham-
operated group during the experiments in Study I. The motility of the colon segment proximal 
to the obstruction was only slightly elevated until 5 h after the obstruction; subsequently, an 
approximately 1.65-fold increase gradually evolved. This change was significant by the end 
of the observation period.  
The KynA treatment significantly inhibited the ileus-induced increase in the motility 
index and decreased the amplitude of the GMCs as compared with the nontreated mechanical 
ileus group (Figure 4A). The tone of the proximal colon was significantly decreased after 
obstruction, and this change was significantly inhibited by KynA treatment after 6 h (Figure 
4B). The frequency of the contractions did not differ in the sham-operated and mechanical 
ileus groups during the observation period (Figure 5B). However, the administration of KynA 
caused a significant elevation in the frequency of the GMCs, which were characterized by a 
decreased amplitude (Figure 5A). 
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Figure 4. Changes in motility index in Study I (A), tone (B) of GMCs of the proximal colon in 
the sham-operated (empty squares with thin continuous line), mechanical ileus (empty 
triangles with continuous line), and KynA-treated mechanical ileus (shaded circles with 
continuous line) groups. An arrow indicates the beginning of obstruction and a gray box the 
infusion of KynA. The plots demonstrate the median values and the 25th (lower whisker) and 
75th (upper whisker) percentiles, * p<0.05 within groups vs baseline values, x p<0.05 between 
groups vs sham-operated group values, # p<0.05 between KynA-treated group vs obstructed 
group values.  
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Figure 5. Changes during Study I in amplitude (A) and frequency (B) of GMCs of the 
proximal colon in the sham-operated (empty squares with thin continuous line), mechanical 
ileus (empty triangles with continuous line), and KynA-treated mechanical ileus (shaded 
circles with continuous line) groups. An arrow indicates the beginning of obstruction and a 
gray box the infusion of KynA. The plots demonstrate the median values and the 25th (lower 
whisker) and 75th (upper whisker) percentiles, * p<0.05 within groups vs baseline values, x 
p<0.05 between groups vs sham-operated group values, # p<0.05 between KynA-treated group 
vs obstructed group values. 
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In Study II, the motility index and the tone of the colon were used as markers to 
estimate the excitatory status of the ENS (Figure 6AB). During the observation period, these 
parameters did not differ significantly from the baseline in the sham-operated group. At the 
beginning of the observation period, the motility index was higher in the TNBS-treated 
groups than in the sham-operated animals and it remained significantly higher during the later 
phase of the experiments.  
After their administration, both NMDA antagonists decreased the motility index, but 
the characteristics of the changes were different. KynA reduced the motility promptly and had 
a shorter effect, while SZR-72 exerted a more gradual and prolonged inhibitory effect. The 
motility effects of the NMDA receptor antagonist compounds were similar 1 h after the end of 
the treatments (i.e. at 20 h of colitis). The tone of the colon gradually decreased in the colitis 
group in response to the inflammation. Administration of the NMDA antagonists in both 
cases significantly reversed the colitis-induced decreased colonic tone, and this parameter in 
these groups did not differ from the level in the sham-operated group. However, the effect of 
KynA was again shorter than that following SZR-72 administration. 
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Figure 6. Changes in motility index in Study II (A) and tone (B) of the colon in the sham-
operated (shaded squares with a thin continuous line), colitis (black diamonds with a thick 
line), SZR-72 (empty circles with a thick line) and KynA-treated colitis (empty triangles with a 
thick line) groups. The box indicates the treatment with NMDA antagonists. The plots 
demonstrate the median values and the 25th (lower whisker) and 75th (upper whisker) 
percentiles, * p<0.05 within groups vs baseline values, x p<0.05 between groups and sham-
operated group values, # p<0.05 between NMDA antagonist-treated groups and colitis group, 
+ p<0.05 between KynA-treated group and SZR-72-treated group values. 
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In Study III, the KynA and SZR-72 per se did not influence the colonic motility 
(Figure 7A). The frequency and amplitude of intestinal movements (Figure 8AB) and the 
colonic tone were used as accurate markers to characterize the motility status of the large 
intestine 6 days after colitis induction; by this stage, the tone did not differ from that in the 
sham-operated controls (Figure 7B). No significant change was observed in the amplitude of 
the contractions in the TNBS-treated groups as compared with the vehicle-treated animals, but 
the frequency of intestinal movements was increased significantly.  
The administration of the NMDA receptor antagonists effectively decreased the rate of 
bowel movements in both treated groups with colitis. KynA treatment significantly increased 
the smooth muscle tone of the intestine 1 h after administration and this elevation was 
maintained until the end of the observation period. SZR-72 caused a similar elevation in the 
colonic tone, which started somewhat later, ~ 2 h after the treatment, and the tone elevation 
likewise persisted until the end of the experiments. 
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Figure 7. Changes on day 6 after enema in motility index (A) and tone (B) of the contractions 
of the proximal colon in the sham-operated (empty squares with thin continuous line), colitis 
(shaded diamonds with solid line), SZR-72 (shaded hexagons with solid line) and KynA-
treated colitis (shaded triangles with solid line) groups. The box indicates the treatment with 
NMDA antagonists. The plots demonstrate the median values and the 25th (lower whisker) 
and 75th (upper whisker) percentiles, * p<0.05 within groups and baseline values, x p<0.05 
between groups and sham-operated group values, # p<0.05 between NMDA antagonist-treated 
group and colitis group. 
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Figure 8. Changes on day 6 after enema in amplitude (A) and  frequency (B) of the 
contractions of the proximal colon in the sham-operated (empty squares with thin continuous 
line), colitis (shaded diamonds with solid line), SZR-72 (shaded hexagons with solid line) and 
KynA-treated colitis (shaded triangles with solid line) groups. The box indicates the treatment 
with NMDA antagonists. The plots demonstrate the median values and the 25th (lower 
whisker) and 75th (upper whisker) percentiles, * p<0.05 within groups and baseline values, x 
p<0.05 between groups and sham-operated group values, # p<0.05 between NMDA antagonist-
treated group and colitis group.   
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5.3. NO production  
NOS activity is responsible for the production of NO, an important regulator of the 
colonic motility. In Study I, after the obstruction we found significantly elevated NOS 
activity. NMDA antagonist KynA treatment was capable of reducing the NOS activity in the 
colonic tissue (Figure 9). 
 Colitis resulted in a significant increase in the total NOS activity over the value for 
the sham-operated group. In Study II, both of the NMDA antagonist treatments significantly 
decreased the colonic NOS activity as compared with the nontreated colitis group (Figure 
10A). 
 
Figure 9. Changes in activity of NOS in Study I, in colonic tissue from sham-operated (empty 
box), mechanical ileus (checked box), and mechanical ileus + KynA-treated (striped box) 
groups. The plots demonstrate the median (horizontal line in the box) and the 25th (lower 
whisker), and 75th (upper whisker) percentiles. x p<0.05 between groups vs sham-operated 
group values, # p<0.05 between KynA-treated groups vs obstructed group values. 
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In the untreated colitis group in Study III, a significant elevation in NOx level was 
observed in the colonic tissue relative to the control. Both NMDA antagonists decreased the 
NOx levels to the control level (Figure 10B). 
 
Figure 10. A: Changes in activity of nitric oxide synthase on day 1 after colitis induction in 
colonic tissue from sham-operated (empty box), colitis (shaded box), KynA-treated colitis 
(striped box) and SZR-72-treated (checked box) groups. The plots demonstrate the median 
(horizontal line in the box) and the 25th (lower whisker), and 75th (upper whisker) percentiles. 
x p<0.05 between groups and sham-operated group values, # p<0.05 between NMDA 
antagonist-treated groups and colitis group values. B: Changes in tissue NOx concentration 
on day 6 after colitis induction in the sham-operated (empty box), colitis (shaded box), KynA-
treated colitis (striped box) and SZR-72-treated (checked box) groups. The plots demonstrate 
the median (horizontal line in the box) and the 25th and 75th percentiles. x p<0.05 between 
groups and sham-operated group values, # p<0.05 between NMDA antagonist-treated groups 
and colitis group values. 
 
5.4. Changes in intestinal XOR activity 
 XOR is activated during the inflammation process and produces a considerable 
amount of superoxide radicals. During the experiments of Study I, in the sham-operated 
group, the XOR activities did not differ significantly. The activity of the superoxide anion-
producing XOR was significantly increased after the colon obstruction. The treatment with 
the nonselective NMDA receptor antagonist significantly inhibited the ileus-induced increases 
in XOR activity (Figure 11A). 
In Study II, 23 h following TNBS treatment, a significant elevation in colonic XOR 
activity was measured relative to the sham-operated group. The KynA and SZR-72 treatments 
each significantly decreased the XOR activity to the level for the sham-operated animals 
(Figure 11B). In Study III, the NMDA antagonist treatment on day 6 was still effective in 
reducing the XOR activity, but SZR-72 was less effective in this case (Figure 11C).  
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Figure 11. A: Changes in activity of XOR in colonic tissue from sham-operated (empty box), 
mechanical ileus (checked box), and mechanical ileus + KynA-treated (striped box) groups. 
The plots demonstrate the median (horizontal line in the box) and the 25th (lower whisker), 
and 75th (upper whisker) percentiles. x p<0.05 between groups vs sham-operated group values, 
# p<0.05 between KynA-treated groups vs obstructed group values. B: Changes in XOR activity 
on day 1 after colitis induction in colonic tissue from sham-operated (empty box), colitis 
(shaded box), KynA-treated colitis (striped box) and SZR-72-treated (checked box) groups. 
The plots demonstrate the median (horizontal line in the box) and the 25th (lower whisker), 
and 75th (upper whisker) percentiles. x p<0.05 between groups vs sham-operated group 
values, # p<0.05 between NMDA antagonist-treated groups vs colitis group values. C: 
Changes in colon XOR activity in the sham-operated (empty box), colitis (shaded box), KynA-
treated colitis (striped box) and SZR-72-treated (checked box) groups. The plots demonstrate 
the median (horizontal line in the box) and the 25th and 75th percentiles. x p<0.05 between 
groups and sham-operated group values, # p<0.05 between NMDA antagonist-treated groups 
and colitis group values. 
 
5.5. In vitro effects of KynA on the luminol-enhanced chemiluminescence generated by 
xanthine/XOR 
The inhibition of chemiluminescence was expressed as a percentage of the control. The 
effects of KynA were examined in the 1 µM - 5 mM concentration range. KynA proved to be 
an effective chemical tool in blocking chemiluminescence generated by the xanthine/XO 
system (Figure 12A). The effects of allopurinol, a specific inhibitor of XOR, were examined 
in the same concentration range and the inhibitory effect of 1 µM allopurinol proved to be 
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nearly the same as that for KynA. Allopurinol at 10 µM and 100 µM was more effective than 
KynA in the same concentration in blocking the chemiluminescence generated by the 
xanthine/XOR system, while a higher (1 mM) allopurinol concentration disturbed the 
chemiluminescence measurements.  
 Dose-dependent effects of KynA on XOR activity were further investigated by in vitro 
fluorometric assay. Between 0,1 mM and 1 mM, KynA effectively inhibited the XOR activity 
by 60-98% of the control. The vechicle did not influence the basic XOR activity (Figure 12B). 
 
Figure 12. Dose-dependent in vitro inhibitory effects of KynA. A: Changes in 
chemiluminescence in the presence of test compounds after induction of the X/XO reaction. 
The degree of inhibition of chemiluminescence was measured with increasing KynA (thick 
line with circles) and allopurinol (thin line with squares) concentrations. B: Inhibitory effects 
of KynA on XO activity in the fluorometric assay. The bars indicate means ± SEM. 
 
5.6. The motility effects of NMDA antagonist treatments in acute, inflammation-associated 
colon disorders in different species 
In all acute GI inflammation models, regardless of the species, an increased bowel 
motility index was observed, accompanied by a decreased tone of the colonic smooth 
muscles. These motility changes were associated with increased levels of inflammatory 
enzyme activities. Regardless of species, the NMDA receptor antagonist treatment was able to 
decrease the motility index, increase the tone and reduce the XOR activity and the level of 
NO production (Table V). It is important to note that TNBS-induced inflammation can be 
identified only 14-17 h following enemas (data not shown) in rodents. This phase was 
considered the acute period of TNBS-induced colitis that is comparable with the early (1-7-h) 
39 
 
period of mechanical ileus-induced inflammation in larger animals. The comparative data 
collected from Studies I-III are shown below.  
 
Species Observation 
time 
Intervention Motility
index 
Bowel 
tone 
NO 
production 
XOR 
activity
Dog 7 hrs Mechanical ileus ↑ ↓ ↑ ↑ 
Ileus + Kyna ↓ ↑ ↓ ↓ 
Wistar 
rat 
17-23 hr Colitis ↑ ↓ ↑ ↑ 
Colitis + KynA ↓↓ ↑ ↓ ↓ 
Colitis + SZR-72 ↓ ↑↑ ↓ ↓ 
Sprague-
Dawley 
rat 
17-23 hr Colitis ↑ ↓ ↑ ↑ 
Colitis + KynA ↓ ↑ ↓ ↓ 
Colitis + SZR-72 ↓ ↑ ↓ ↓ 
 
Table V. Data on mechanical ileus and colitis in dogs and rats (for the sake of clarity, other 
time frames of colitis (between 17 and 23 h) of Sprague-Dawley rats are not presented in 
other parts of the thesis). 
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6. DISCUSSION 
Local inflammation is either the inducer of GI motility changes or is associated with 
altered motility. The entire integrative circuitry for enteric reflexes is located in the wall of the 
small intestine and colon, and the production of inflammatory mediators and metabolites 
therefore has significant consequences in the pathogenesis of all motility disorders (Lakhan et 
al. 2010, Törnblom et al. 2005). Indeed, the activation of resident macrophages in the tunica 
muscularis and the upregulated cytokine production may affect the smooth muscle 
contractility (Won et al. 2006). There is now good evidence that a postoperative ileus initiates 
the activation of transcription factors, upregulates proinflammatory cytokines, and increases 
the release of kinetically active mediators (inducible NO and prostaglandins), important 
factors in the recruitment of leukocytes and the suppression of motility (Kalff et al. 2003).  On 
the other hand, Hellström et al. have demonstrated that low doses of endotoxin change the 
myoelectric activity in the small intestine, with repetitive bursts of spike potentials and a 
simultaneous increase in the transit of the intestinal contents (Hellström et al. 1997). On the 
basis of these observations, it should be emphasized that motility alterations are time-
dependent, characteristically changing in parallel with the modified neurotransmitter release, 
or the impairment of the function of the enteric neurons during the development of 
inflammation (Kaszaki et al. 1987).  
We used a study design to follow the steps of the pathways leading to inflammation-
associated colon motility changes. First we investigated the time course of inflammatory and 
motility changes in the large intestine in acute mechanical ileus. Experimental blockade of the 
passage increased the large bowel motility 5 h after obstruction, and triggered significant NO 
production and XOR activation in the proximal colon (Palásthy et al. 2006). The nonselective, 
natural NMDA receptor antagonist KynA decreased the motility index, together with the NOS 
activity and ROS produced by XOR, which indicated that glutamate-NMDA receptors 
contribute to the excitatory profile of the motility pattern in the early phase of the 
inflammatory process (Kaszaki et al. 2008). The relative weight of KynA treatment in the 
modification of the obstruction-induced motility dysfunction was significant. 
As next step, the role of glutamate receptors was further investigated in the early and 
later phases of TNBS-induced colitis. In this model, enhanced colon motility was present at 
17-23 h, but 5-7 days later the motility had decreased significantly. Our results are consistent 
with the findings of Gurung et al. (Gurung et al. 2007), and the different patterns of the early 
and the later motility changes may be ascribed to different responses to neurotransmitters 
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(Hosseini et al. 1999). Hypermotility in the early phase is a sign of increased excitation in the 
ENS, while the later decrease in motility reflects the ensuing overexcitatory damage of the 
myenteric plexus and the loss of the regulatory function of the ENS. It should be noted here 
that glutamate neurotoxicity (necrosis and apoptosis) has been observed in a subset of enteric 
neurons in both intact bowel preparations and cultured myenteric ganglia (Kirchgessner et al. 
1997). 
The inflammatory and motility changes in TNBS-induced colitis were effectively 
modified by KynA and also by treatment with SZR-72, a BBB-permeable synthetic KynA 
analog (Knyihár-Csillik et al. 2008, Varga et al. 2010). Since KynA is unable to penetrate the 
BBB (Kiss et al. 2005), the iv administered compound acted at the periphery only and 
targeted the NMDA receptors of the ENS. In these studies, both treatments decreased the 
motility index significantly, normalized the smooth muscle tone of the colon to the control 
level and exerted an inhibitory effect on the colitis-induced high NOS and XOR activities in 
the early phase of colitis. This effect of NMDA antagonists suggests that the glutamate 
receptors mainly contribute to the excitatory profile of the motility pattern and inflammation 
in the examined time frame (Varga et al. 2010). 
6.1. Role of NMDA receptors in primary motility disorders: Study I  
The results of Study I have revealed a significant potential for KynA to decrease the 
facilitatory pathways of the colonic motility. Our study design allowed us to follow the 
variations in time of the inflammatory and motility changes in the large intestine in the acute 
phase of mechanical ileus, and to investigate the role of the glutamate receptors in this 
scenario. In this canine model, experimental blockade of the intestinal passage increased the 
large bowel motility, and triggered a hyperdynamic circulatory reaction 5 h after obstruction, 
accompanied by significant NO production and XOR activation in the proximal colon. This 
hyperdynamic cardiovascular response may be regarded as a compensatory reaction through 
which the organism strives to accommodate to the evolving septic metabolic changes (Bone et 
al. 1991, Palásthy et al. 2006). 
It is clear that, besides being one of the main excitatory transmitters in the CNS, 
glutamate can act either as a neurotransmitter in the peripheral nervous system or at least as a 
modulator of classical transmitter systems (Liu et al. 1997, Kirchgessner et al. 2001, Wiley et 
al. 1991, Sinsky et al. 1998). In particular, there is now evidence for glutamate release from 
neurons and the presence of glutamate receptors in the intestine in nonhuman species (Ren et 
al. 1999), and receptors of the NMDA subtype in the myenteric plexus (Moroni et al. 1986). 
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This subtype is preferentially activated by quinolinic acid and blocked by KynA (Stone et al. 
2003, Perkins et al. 1982, Stone et al. 2001). These data therefore indicated that NMDA 
subtype receptors play a role in the gut motility, and activation by glutamate could increase 
the contractile activity. Our results have revealed that glutamatergic facilitation does indeed 
take part in an obstruction-induced increase in colon motility. 
The enzymes of the kynurenine pathway are activated by inflammation and immune 
stimulation, leading to large increases in the generation of the NMDA agonist quinolinic acid 
and its antagonist, KynA (Stone et al. 2001, Mackay et al. 2006). The balance between the 
relative concentrations of these substances during an inflammatory response could therefore 
have a profound influence on the excitability of the enteric neurons and hence on the motility 
of the gut (Forrest et al. 2002, 2003). Moreover, quinolinic acid can increase the formation of 
ROS, both through a direct Fenton-like interaction with iron, and through the NMDA 
receptor-activated increase in intracellular Ca2+ level, which results in a higher XOR activity 
(Rios et al. 1991).  
The relative weight of KynA treatment in the modification of the ileus-induced 
motility dysfunction was significant. Our results indicate that mainly glutamate receptors 
contribute to the excitatory profile of the motility pattern in the examined time frame, since 
nonselective NMDA receptor antagonism treatment significantly decreased the motility index 
and amplitude of the GMCs.  
The link between constitutive NO production and the gastrointestinal nervous system 
is of special interest (Ekblad et al. 1994, Furness et al. 2000, Qu et al. 1999). For transmitter 
release, nNOS permits the rapid release of NO, and this process is associated with the 
translocation of cytosolic nNOS to the cell membrane. There, it is bound to postsynaptic 
density 95 protein in intimate association with NMDA glutamate receptors, permitting a direct 
route for Ca2+ through the NMDA receptor channel to nNOS. The excessive accumulation of 
glutamate with subsequent activation of the ligand-gated, ion channel NMDA glutamate 
receptors appears to result in excitotoxicity due to the breakdown of ionic homeostasis, 
stimulation of nNOS activity with the increased production of NO leading to the formation of 
ROS and nitroso species (Liu et al. 1997, Furness et al. 2000). These results suggest that 
neuroprotection against glutamate by KynA might be mediated synergistically through the 
blockade of NMDA receptors and inhibition of nNOS. 
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6.2. Neuroprotection in inflammation-induced motility disorders: Studies II and III 
The applied TNBS enema causes extensive transmural colitis that usually lasts longer 
than 8 weeks in rodents. This experimental IBD model is characterized by a weight loss with 
visceral hyperalgesia (Zhou et al. 2008), significant elevations of NOS activities (Kiss et al. 
1997, Yue et al. 2001) and tissue granulocyte accumulation (Kiss et al. 1997). The 
development of TNBS-caused colonic inflammation shares many similarities with fulminant 
episodes of human IBDs, but the acute motility consequences differ from the later changes. In 
this regard, we designed two studies to monitor the motility and inflammatory changes in the 
large intestine during the early onset and in a later, more established phase of the 
inflammation after an acute TNBS challenge.  
On day 1, the intracolonic TNBS administration enhanced the large bowel motility 
significantly and induced serosal hyperemia with a hyperdynamic macrocirculatory reaction. 
These changes were accompanied by tissue NOS and XOR activation in the proximal colon. 
The study design additionally allowed us to investigate the functional role of the NMDA 
glutamate receptors; the results revealed a significant potential for NMDA receptor 
antagonists to decrease both inflammatory activation and the parallel facilitation of colonic 
motility in this scenario. 
However, the later phase of the established inflammation on day 6 was characterized 
by normal systemic hemodynamics, accompanied by biochemical signs of nitrosative stress. 
According to our observations in Studies II and III, differences between the two phases were 
truly present. The colon was hypermotilitic on the first day after TNBS enema administration, 
and the analysis of the motility parameters on day 6 furnished evidence of a tendency to a 
return toward normal homeostasis (Kaszaki et al. 2012). These differences may be ascribed to 
time-dependent responses to neurotransmitters; early hypermotility is a sign of increased 
excitation in the ENS (Hosseini et al. 1999). The ensuing loss of the regulatory neural 
function is clearly multifactorial, but several lines of indirect evidence have suggested a role 
for NMDA receptors in this scenario. Glutamate neurotoxicity (necrosis and apoptosis) has 
been observed in a subset of enteric neurons in both intact bowel preparations and cultured 
myenteric ganglia (Kirchgessner et al. 1997). In Study I, we demonstrated that treatment with 
the NMDA receptor antagonist KynA decreased the obstruction-caused intestinal 
hypermotility in dogs, and the use of specific antagonists to block NMDA receptors had 
similar effects in an acute TNBS-induced colitis model in rats (Kaszaki et al. 2008, Varga et 
al. 2010).  
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However, there were no significant changes in hemodynamics on day 6 after the 
TNBS enema; during the early phase of colitis evolution, the barrier function of the mucosal 
epithelium was rapidly lost (Appleyard et al. 2002, Krimsky et al. 2003), leading to bacterial 
translocation and a characteristic cardiovascular response. The hyperdynamic process is 
regarded as a compensatory change through which the organism strives to accommodate to 
the emerging septic metabolic changes (Bone et al. 1991). In TNBS-treated animals, this 
reaction was evidenced by decreased MAP and TPR and elevated CO levels. Treatment with 
the NMDA receptor antagonist KynA did not significantly influence the overall 
hemodynamics, but the analog SZR-72 caused a moderate TPR elevation. The difference 
between the systemic circulatory effects of the examined NMDA antagonists may be linked to 
the divergent permeabilities of SZR-72 and KynA through the BBB. This assumption is 
supported by the observation that L-glutamate and NMDA microinjection into the nucleus 
tractus solitarius produced dose-dependent decreases in blood pressure, mesenteric blood flow 
and iliac vascular resistance. However, previous administration of the NMDA receptor 
antagonist MK-801 into the same CNS area significantly attenuated this NMDA-induced 
depressor effect (Tian et al. 1994). Unlike KynA (Bari et al. 2006, Vécsei et al. 1992), SZR-
72 readily crosses the BBB and in this way peripheral hemodynamic reactions may be 
modulated by CNS effects.  
A further important feature of NMDA receptor antagonist treatment modalities was the 
parallel influence on distinct elements of the inflammatory response, including the inhibition 
of local NO synthesis. The matching effects on the microcirculatory, motility and biochemical 
responses may be indicative of a connection between the action on local NMDA receptors and 
the NOS systems. Indeed, the in vitro study by Lomax et al. provided evidence that the altered 
neural regulation of the gastrointestinal microvasculature contributes significantly to the 
pathogenesis of TNBS colitis (Lomax et al. 2007). 
It has recently been demonstrated that NMDA receptors are expressed not only on 
neurons, but also on a number of non-neuronal cell types, including endothelial cells and 
immune-competent cells, and this points to the action of a common regulatory mechanism 
(Boldyrev et al. 2004, Hinoi et al. 2004, Miglio et al. 2005, Reijerkerk et al. 2010). Indeed, 
Mashkina et al. (2010) have established that the population of inactive lymphocytes contains 
only a few cells with NMDA receptors, and expression is induced after appropriate stimuli. 
Moreover, it has been reported that NMDA receptor expression and a normal function are 
required for activation of the respiratory burst of PMN granulocytes (Kim-Park et al. 1997). 
On the other hand, NMDA activation by glutamate can alter the ion balance between the 
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intra- and the extracellular space by elevation of the intracellular Ca2+ level, and the increased 
Ca2+ influx may result in excitotoxicity. It is therefore suggested that a regulatory interplay 
between the neuronal and cellular immune systems is highly likely in the gastrointestinal tract 
through NMDA receptor activation. 
The pathogenic role of NO-derived species such as peroxynitrite in IBDs is supported 
by the fact that the intracolonic administration of exogenous peroxynitrite induces severe 
inflammation, which mimics the features of human ulcerative colitis. Peroxynitrite produced 
by the reaction of NO with superoxide is highly cytotoxic and able to induce structural 
damage (Ko et al. 2005, Linden et al. 2005). ROS produced in the inflamed mucosa are 
mainly generated by activated phagocytic leukocytes via NADPH oxidase and the XOR 
system. The colonic XOR activity was elevated significantly 6 days after TNBS induction, 
although the level was somewhat lower than in the early phase of colitis (Varga et al. 2010).  
In Study III, we have demonstrated that the amplitude of the contractions and the tone 
of the colonic smooth muscle have normalized by day 6, but the frequency of bowel 
movements is still increased over the baseline level. This implies that the regulation of 
frequency involves the distinct action of a mediator or a regulatory system; indeed, the 
relevant literature data suggest that this response may be linked to NO and altered NO 
synthesis. Bossone et al. (2001) reported that the contraction frequency changes observed 
after repeated applications of TNBS are critically connected to the activation of iNOS. In 
Study II, we also presented evidence of the role of activation of the NMDA receptors in NO 
synthesis in the colonic tissue. It was found that on day 6 the TNBS-induced increased 
peristaltic frequency is associated with significantly increased plasma NOx levels. It is 
important to note that an augmented Ca2+ influx through the NMDA receptor-ion complex 
may stimulate Ca2+-dependent NO synthesis (Petersson et al. 2007, Yue et al. 2001). Thus, the 
data might suggest that activation of the ligand-gated, ion channel NMDA glutamate receptors 
can lead to the stimulation of cNOS isoforms (endothelial NOS and nNOS), with increased 
NO production and an increased frequency of intestinal contractions. The activation of 
NMDA receptors seems to be critically involved in this phenomenon since the inhibition of 
the NMDA receptors by the NMDA antagonists markedly decreased the rate of contractions. 
Our results demonstrated that enhanced colon motility is present after 17–23 h of 
colitis, but in the later phase (on day 6) the motility usually decreases (Gurung et al. 2008). 
The different patterns of the early and the later motility changes may be ascribed to different 
responses to neurotransmitters (Hosseini et al. 1999). Hypermotility in the early phase is a 
sign of the increased excitation in the ENS, while the ensuing decrease in motility reflects 
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overexcitatory damage of the neurons of the myenteric plexus and loss of the regulatory 
function of the ENS. Both KynA and SZR-72 treatments decreased the motility index 
significantly and normalized the smooth muscle tone of the colon to the control level in Study 
II. This effect of NMDA antagonists in the early phase of colitis suggests that the glutamate 
receptors mainly contribute to the excitatory profile of the motility pattern in the examined 
time frame.  
6.3. KynA directly inhibits XOR activity in vitro 
Besides the motility-influencing effects, KynA is inhibitory on the activity of XOR in 
vivo. A possible explanation for the decreased XOR activity could be a substrate analog, 
nonspecific inhibitory effect of KynA, since there is structural similarity to 
hypoxanthine/xanthine, the substrate for XOR. Therefore, a series of investigations in a cell-
free, in vitro environment were designed to gain insight into the direct effects of KynA on the 
XOR activity. Indeed, the effect of KynA on the activity of XOR was assessed for the first 
time, and a significant inhibitory potential was observed for the compound. These findings 
reveal that KynA not only significantly influences the motility pattern in the colon, but also 
exerts a protective, anti-inflammatory effect due to direct and indirect inhibition of XOR-
derived oxygen radical production. Our results further indicate that KynA may offer a 
pharmacologic approach to inhibit XOR activity in the GI tract. 
 
It remains to be established whether the findings in these experimental models are 
applicable to humans. However, together with previous observations, these data strongly 
suggest that suppression of the hypermotility function of the NMDA receptors might be 
beneficial in serving as a supplementary tool with which to influence excitotoxicity 
complications in the intestine. In conclusion, since the etiopathogenesis of inflammation-
associated motility disorders is multifactorial, multifunctional therapy is clearly required to 
address the various pathological aspects of these diseases. In this regard, we suggest that the 
blockade of enteric NMDA receptors might provide greater therapeutic efficacy by targeting 
motility and local inflammatory changes. 
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7. SUMMARY OF FINDINGS 
• NMDA receptor antagonist treatment effectively influences the colonic motility 
changes (increased motility index and decreased smooth muscle tone) during acute 
inflammation. This suggests that the activation of enteric NMDA-sensitive glutamate 
receptors participates in the mediation of inflammation-related motility changes in the 
GI tract. 
• Parallel to the motility reactions, nonselective NMDA receptor antagonist treatment 
decreases pro-inflammatory activation in the colon. We demonstrated for the first time 
the direct inhibitory effect of KynA on the XOR activity, and thus the anti-
inflammatory effect of KynA could be related to the elimination of XOR-dependent 
oxygen radical production in the colon. 
• The significant anti-inflammatory effects of NMDA antagonist treatment can be 
detected even at later phases of inflammation (beyond 6 days) in experimental colitis.  
• The peripheral administration of KynA and its BBB-permeable analog SZR-72, 
proved to be equally effective in this condition. 
• NMDA antagonist treatment was capable of influencing the motility and inflammatory 
changes in different models of colonic inflammation, which strongly indicates that 
glutamate-induced neurotoxicity has a basic role in the pathogenesis of inflammation-
associated GI motility disorders in a species-independent manner. 
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